

SEIZURE PROPHYLAXIS IN THE NEUROICU

Amanda Rivera, Stephanie Seto, and Megan E. Barra



INDICATION	INCIDENCE	ROUTINE PROPHYLAXIS INDICATED	RECOMMENDATIONS
Traumatic brain injury (TBI) [1]	4–42%	+	<ul style="list-style-type: none"> – Administer empiric prophylaxis for 7 days post-injury – More beneficial in early vs. late PTS – Agents: Preferred – levetiracetam, phenytoin
Aneurysmal subarachnoid hemorrhage (aSAH) [2]	1–18%	+/-	<ul style="list-style-type: none"> – Administer empiric prophylaxis until aneurysm is secured – Short-course (3–7 days) prophylaxis preferable if indicated – Phenytoin is not recommended routinely for seizure prophylaxis
Brain neoplasm [3]	10–45%	⊘	<ul style="list-style-type: none"> – Routine prophylaxis not recommended as shown to be ineffective in preventing first seizure and have potential side effects – No benefit shown in patients undergoing supratentorial meningioma resection or in metastatic brain tumors – A short course may be indicated postoperatively in patients presenting with seizures
Intracerebral hemorrhage [4, 5]	5.5–24%	⊘	<ul style="list-style-type: none"> – Insufficient evidence to support the use of prophylactic AEDs
Ischemic stroke [3]	4–23%	⊘	<ul style="list-style-type: none"> – Risk factors: hemorrhagic conversion, cortical involvement, involvement of >1 lobe – Insufficient evidence to support the use of prophylactic AEDs
Postoperative craniotomy [3]	15–20%	⊘	<ul style="list-style-type: none"> – Limited evidence to support the prophylactic use of AEDs in post neurosurgery patients – Levetiracetam preferred over phenytoin (due to lower ADEs)
Vascular lesions [3]	Variable	⊘	<ul style="list-style-type: none"> – Insufficient evidence to support the use of prophylactic AEDs
Cerebral venous thrombosis (CVT) [3]	Up to 40%	⊘	<ul style="list-style-type: none"> – Insufficient evidence to support the use of prophylactic AEDs

INDICATION	INCIDENCE	ROUTINE PROPHYLAXIS INDICATED	RECOMMENDATIONS
Posterior reversible leukoencephalopathy syndrome (PRES) [3]	Up to 68.8%	⊘	– Insufficient evidence to support the use of prophylactic AEDs
Meningitis [3]	Up to 27%	⊘	– Insufficient evidence to support the use of prophylactic AEDs

+ = routine prophylaxis indicated, +/- = may consider routine prophylaxis, ⊘ = routine prophylaxis not indicated*

*Use best judgment in cases where routine prophylaxis is not advised, as it may be indicated on a case-by-case scenario.

REFERENCES

1. Yerram S, Katyal N, Premkumar K, Nattanmai P, Newey CR. Seizure prophylaxis in the neuroscience intensive care unit. *J Intensive Care*. 2018;6(1):17.
2. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N, Rubiano AM. Guidelines for the management of severe traumatic brain injury. *Neurosurgery*. 2017;80(1):6–15.
3. Gilmore EJ, Maciel CB, Hirsch LJ, Sheth KN. Review of the utility of prophylactic anticonvulsant use in critically ill patients with intracerebral hemorrhage. *Stroke*. 2016;47(10):2666–72.
4. Hemphill JC III, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2015;46(7):2032–60.
5. Diring MN, Bleck TP, Hemphill JC, Menon D, Shutter L, Vespa P, Bruder N, Connolly ES, Citerio G, Gress D, Hänggi D. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. *Neurocrit Care*. 2011;15(2):211.